Yu Meng

Xinyu Pharmaceutical Co., Ltd. engages in the research, development, and production of microbial pharmaceuticals. Its key products are the active pharmaceutical ingredient lincomycin hydrochlorlde and its derivatives, which include clindamycin hydrochloride and clindamycin phosphate, as well as neomycin sulphate, moxidectin, framycetin sulphate, tenofovir disoproxil fumarate, nosihepitde premix, and enramycin premix. The company was founded in 1988 and is headquartered in Suzhou, China.